None listed
Conditions
Brief summary
This trial examines whether a new dialysis membrane has potential advantages to the patients by way of determining whether the membrane results in less of an inflammatory state - reflected by both markers of inflammation and nutrition in the blood. It is a short term pilot study only, as a possible lead in to a longer more detailed study. The dialysis membranes will be supplied blinded in that all will look the same (but carry a code) such that the treating dialysis nurses and the patients will be unaware of which dialyser is in use at any given time.
Interventions
30 stable haemodialysis patients will be randomly assigned to either continue on conventional high-flux dialysis with the FX60 membrane or the new modified-FX membrane. Equal numbers in each group. Cross-over after 6 weeks. Total study duration 12 weeks.
Sponsors
Fresenius
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Stable haemodialysis patients, currently dialysed with FX60 dialysers.
Exclusion criteria
No exclusion criteria
Outcome results
None listed